The Hourly View for Merck
- At the moment, MRK’s price is up $0.01 (0.01%) from the hour prior.
- Merck has seen its price go down 4 out of the past 5 hours, thus creating some compelling opportunities for bears.
- As for the trend on the hourly timeframe, we see the clearest trend on the 100 hour timeframe.
- The moving averages on the hourly timeframe suggest a bullishness in price, as the 20, 50, 100 and 200 are all in a bullish alignment — meaning the shorter durations are above the longer duration averages, implying a sound upward trend.
Merck’s hourly price chart is shown below.
The Daily View for Merck
- At the time of this writing, MRK’s price is up $0.22 (0.28%) from the day prior.
- Merck has seen its price go up 4 out of the past 5 days, thus creating some compelling opportunities for bulls.
- Regarding the trend, note that the strongest trend exists on the 20 day timeframe.
- Price action traders may also wish to note that we see a pin bar candlestick pattern on Merck. Given that we see an uptrend on the 10 daily candle timeframe, and that such candlestick patterns often denote reversals, this may be worth noting.
- The moving averages on the daily timeframe suggest a choppiness in price, as the 20, 50, 100 and 200 are all in a mixed alignment — meaning the trend across timeframes is inconsistent, indicating a potential opportunity for rangebound traders.
Below is a daily price chart of Merck.
Latest News Discussing MRK
- Pharma Stock Roundup: FDA Nod for MRK, PFE Products & New Use of LLY, GSK Drugs – Kinjel Shah
August 20, 2021FDA approves Merck’s (MRK) Welireg and Pfizer’s (PFE) TICOVAC vaccine and new indications for Lilly’s (LLY) Jardiance and Glaxo’s (GSK) Jemperli.
- Gilead (GILD) MAA for HIV Inhibitor Under the EMA’s Review – Zacks Equity Research
August 20, 2021Gilead’s (GILD) application for an investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, is under review with the European regulatory body.
- The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck – Shanthi Rexaline
August 19, 2021Here’s a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)AbbVie Inc. (NYSE: ABBV)
Alkermes plc (NASDAQ: ALKS)
Bio-Rad Laboratories, Inc. (NYSE: BIO)
Crineti…
The post Merck is Up for the 2nd Day in a Row appeared first on CFDTrading.
This post first appeared on Complete CFD Trading Guide, News And Analysis, please read the originial post: here
